drugset / Trial / NCT05511844
Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase 1 first-in-human study of ORM-5029 in participants with HER2-expressing advanced solid tumors. The study consists of two parts: a Part 1 Dose Escalation and Part 2 Dose Expansion.
Timeline
- Start
- 2022-10-03
- Primary completion
- 2025-06-02
- Completion
- 2025-06-02
Outcome
Outcome not reported
Stopped (Business): “Sponsor Decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORM-5029 | Unknown | — | Intravenous |